InsidersTradesSigma
申报总数
公司
▲ 买入（3 笔）
▼ 卖出（0 笔）
内部人交易记录
首席执行官已披露买入
3
已披露卖出
0
T+90 胜率
0%
T+90 平均收益
-41.4%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Explore the complete record of transactions filed by Drachman Jonathan G, 董事长兼首席执行官. Officer active across 3 companies, notably Neoleukin Therapeutics, Inc.. Aggregated, 5 disclosures have been recorded. Breakdown: 3 buys · 0 sell. Total volume traded: €833k. Activity tracked since 3 June 2021. The latest transaction was disclosed on 8 March 2024 (Attribution). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Drachman Jonathan G
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报5 总计
415 股0Common StockSEC:0000950170-24-029434:0
5,000 股0Common StockSEC:0001209191-23-056795:0
200,000 股@ €0.741250.0% 占其流量Common StockSEC:0000899243-21-044150:0
标准退出：2022年2月8日 (T+90)
100,000 股@ US$6.11162.5% 占其流量Common StockSEC:0001209191-21-053544:0
标准退出：2021年11月22日 (T+90)
40,000 股@ US$9.481837.5% 占其流量Common StockSEC:0001209191-21-038690:0
标准退出：2021年9月1日 (T+90)
5 条申报中的 5 条
About Drachman Jonathan G
Jonathan G. Drachman is President and CEO of Neoleukin Therapeutics, Inc. and Calithera Biosciences, Inc. He leads these companies with a strategic vision, overseeing all operations and ensuring performance objectives are met. His leadership is crucial for the development of these biopharmaceutical firms.
